ScaleWiki
Explore our comprehensive collection of scientific resources, from application notes and case studies to videos and webinars.
Share
Filter By
Cell Types
Filter by G- Rex Models
Filter by Year
Publications
CAR T Cells
A Rapid Approach to Streamlined CART Therapies and Reduced Cost of Goods
Kincell Bio partnered with Syenex to evaluate the RapidCell engineered vector for CD19-targeting CAR-T manufacturing. The vector eliminates activation reagents and isolation steps, reducing processing time by 40% and cost of goods by 55%. G-Rex is not referenced in this document.
Publications
TCR T Cells
G-Rex100M, G-Rex6M – 2cm²
Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro
A 10-day clinical-scale TCR-T manufacturing protocol using IL-2, IL-7, IL-15, and TGF-β generates KRAS G12D-targeting cells enriched in early memory and tissue-resident phenotypes. G-Rex 6M-2 bioreactors were used for small-scale and G-Rex 100M flasks for clinical-scale expansion, yielding 3.3-6.15 x 10⁹ cells.
Publications
B Cells, CAR T Cells, NK Cells, NKT Cells
G-Rex500M
A streamlined, end-to-end solution for robust and efficient large-scale CAR T manufacturing
Miltenyi Biotec evaluates four automated CAR T cell manufacturing workflows. The study compares CliniMACS Prodigy and CliniMACS Plus systems for scalability. A G-Rex 500M bioreactor is paired with the CliniMACS Plus instrument to support automated cell enrichment and expanded culture capacity.
Publications
Other
Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application
This guidance describes FDA CMC flexibilities for human cell and gene therapy products. It details approaches for clinical development, process validation, and specifications. G-Rex is not referenced in this document.
Publications
Other
Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products
This guidance discusses methods for capturing postapproval safety and efficacy data for cell and gene therapy products. It explores the use of real-world evidence, electronic health records, and registries. G-Rex is not referenced in this document.
Publications
Other
Considerations for the use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause
This document describes the Plausible Mechanism Framework for developing individualized therapies for specific genetic conditions. It covers regulatory, nonclinical, clinical, and CMC considerations. G-Rex is not referenced in this document.
Publications
Other
Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations
This guidance outlines innovative clinical trial designs for cell and gene therapy products in small populations. It details single-arm trials, disease progression modeling, and adaptive designs. G-Rex is not referenced in this document.
Publications
CD34 Cells
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
This draft guidance provides recommendations for expedited development and review of regenerative medicine therapies for serious conditions. It outlines programs like RMAT, fast track, and breakthrough designations. G-Rex is not referenced in this document.
